Neutrophils Fuel Effective Immune Responses through Gluconeogenesis and Glycogenesis

Pranvera Sadiku, Joseph A Willson, Eilise M Ryan, David Sammut, Patricia Coelho, Emily R Watts, Robert Grecian, Jason M Young, Martin Bewley, Simone Arienti, Ananda S Mirchandani, Manuel A Sanchez Garcia, Tyler Morrison, Ailing Zhang, Leila Reyes, Tobias Griessler, Privjyot Jheeta, Gordon G Paterson, Christopher J Graham, John P Thomson, Kenneth Baillie, A A Roger Thompson, Jessie-May Morgan, Abel Acosta-Sanchez, Veronica M Dardé, Jordi Duran, Joan J Guinovart, Gio Rodriguez-Blanco, Alex Von Kriegsheim, Richard R Meehan, Massimiliano Mazzone, David H Dockrell, Bart Ghesquiere, Peter Carmeliet, Moira K B Whyte, Sarah R Walmsley, Pranvera Sadiku, Joseph A Willson, Eilise M Ryan, David Sammut, Patricia Coelho, Emily R Watts, Robert Grecian, Jason M Young, Martin Bewley, Simone Arienti, Ananda S Mirchandani, Manuel A Sanchez Garcia, Tyler Morrison, Ailing Zhang, Leila Reyes, Tobias Griessler, Privjyot Jheeta, Gordon G Paterson, Christopher J Graham, John P Thomson, Kenneth Baillie, A A Roger Thompson, Jessie-May Morgan, Abel Acosta-Sanchez, Veronica M Dardé, Jordi Duran, Joan J Guinovart, Gio Rodriguez-Blanco, Alex Von Kriegsheim, Richard R Meehan, Massimiliano Mazzone, David H Dockrell, Bart Ghesquiere, Peter Carmeliet, Moira K B Whyte, Sarah R Walmsley

Abstract

Neutrophils can function and survive in injured and infected tissues, where oxygen and metabolic substrates are limited. Using radioactive flux assays and LC-MS tracing with U-13C glucose, glutamine, and pyruvate, we observe that neutrophils require the generation of intracellular glycogen stores by gluconeogenesis and glycogenesis for effective survival and bacterial killing. These metabolic adaptations are dynamic, with net increases in glycogen stores observed following LPS challenge or altitude-induced hypoxia. Neutrophils from patients with chronic obstructive pulmonary disease have reduced glycogen cycling, resulting in impaired function. Metabolic specialization of neutrophils may therefore underpin disease pathology and allow selective therapeutic targeting.

Keywords: COPD; GYS1; gluconeogenesis; glycogen; glycogenesis; glycogenolysis; glycolysis; inflammation; neutrophil.

Conflict of interest statement

Declaration of Interests The authors declare no competing interests.

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
Neutrophil Stimulation Results in Upregulated Glycolytic and PPP Activity, Redox Buffer Capacity, and Glutamine Utilization (A–C) Radioactive flux assay analysis of human neutrophils following 6 h of culture showing glycolysis (A), TCA/PPP cycle (B), and fatty acid oxidation (FAO) (C) in unstimulated and stimulated neutrophils under normoxic (N, 21% O2, white bar) and hypoxic (H, 1% O2, gray bar) culture. (A) N and N + LPS, n = 12; N + 2-DG, n = 6; N + LPS + 2-DG, n = 4; H and H + LPS, n = 11; H + 2-DG, n = 5; H + LPS + 2-DG, n = 3. (B) n = 4 for all conditions. (C) N and N + LPS, n = 6; H and H + LPS, n = 5; N + etomoxir and H + etomoxir, n = 3. (D) A pathway diagram showing the metabolites measured in human neutrophils following 6 h of culture in normoxia and hypoxia in the presence or absence of LPS stimulation. (E–L) LC-MS analyses of the neutrophil intracellular abundance of glycolytic metabolites (glucose-6-phosphate/fructose-6-phosphate, G6P/F6P; dihydroxyacetone phosphate, DHAP; glyceradehyde-3-phosphate, GAP; lactate), pentose phosphate pathway metabolites (PPP; ribose-5-phosphate/xylulose-5-phosphate, R5P/X5P; sedoheptulose-7-phosphate, S7P), and redox buffers (NADPH and NADH). n = 3. (M and N) LC-MS time course analyses of the neutrophil intracellular levels of amino acid glutamine (M; n = 3) and percentage heavy labeled glutamate (N; n = 3) following culture with U-13C glutamine. Data represent mean ± SEM. p values obtained via unpaired t tests (A–C), paired t tests (D–L), or two-way ANOVA with Tukey’s multiple comparisons test; overall significance shown for increase in labeled glutamate from 2 to 6 h (N). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005, ∗∗∗∗p < 0.001.
Figure 2
Figure 2
Neutrophil ATP Is Predominantly Generated by Glycolysis with Maintenance of Energy Charge during Neutrophil Lifespan and in a Glucose-Deplete Setting (A and B) ATP contribution of fatty acid oxidation (FAO), tricarboxylic acid cycle (TCA), and glycolysis were derived from calculation from the radioactive flux assays comparing normoxia to hypoxia (A) and unstimulated to LPS-stimulated neutrophils following 6 h of culture (B). Normoxia, FAO, n = 6; TCA, n = 3; glycolysis, n = 9; hypoxia, FAO, n = 4; TCA, n = 3; glycolysis, n = 8: normoxia + LPS, FAO, n = 6; TCA, n = 3; glycolysis, n = 9. (C–E) Energy status measurement (ATP/ADP) of neutrophils cultured for 2 h in the presence and absence of pathway inhibitors 10 mM 2-DG (C; n = 4), 1.2 μM oligomycin A (D; n = 3), and 10 μM etomoxir (E; n = 3). (F and G) Energy charge measurement ([ATP + 1/2ADP]/[ATP + ADP + AMP]) in neutrophils cultured for 2, 6, and 20 h in normoxia and hypoxia (F) and for 12 h in glucose-replete and -deplete medium in unstimulated and LPS-stimulated cells (G). (F) normoxia + LPS-glucose, n = 4; hypoxia + glucose, n = 3. (G) n = 3. Data represent mean ± SEM. p values obtained via unpaired t test (A and B) or paired t test (C). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005, ∗∗∗∗p < 0.001.
Figure 3
Figure 3
Regulation of Glycogen Stores and Gluconeogenesis Pathway Activity during Human Neutrophil Activation (A) Glycogen level quantification in freshly isolated neutrophils (0 h) and following 6 h of culture in glucose-deplete and -replete media under normoxia and hypoxia. n = 4. (B) Glycogen content of neutrophils following 6 h of normoxic culture with the glycogen phosphorylase inhibitor CP-91149 preventing glycogen breakdown. n = 4. (C) Assessment of apoptosis rates using flow cytometry following culture in glucose-deprived media under normoxia and hypoxia with CP-91149 and LPS for 12 h. n = 5. (D and E) Liquid scintillation count measurement of radioactive U-14C glucose (D; n = 4) and U-14C lactate (E; n = 5) incorporation into neutrophil glycogen stores following 6 h of culture. (F) Transcript expression of glycogen metabolism and gluconeogenesis machinery: muscle glycogen synthase (GYS1, n = 4), glycogen branching enzyme (GBE1, n = 4), UDP-glucose pyrophosphorylase 2 (UGP2, n = 3), liver glycogen phosphorylase (PYGL, n = 4), fructose-1,6-bisphosphatase 1 (FBP1, n = 4), and phosphoenolpyruvate carboxykinase 2 (PEPCK2, n = 4). (G) Protein expression of glycogen metabolism and gluconeogenesis machinery in freshly isolated neutrophils (0 h) and neutrophils cultured for 6 or 20 h. Positive controls for FBP1 and PEPCK2− MCF7 lysate, PYGL− mouse liver lysate, phospho-GYS (p-GYS), and GYS− NIH/3T3 cell lysate. Representative western blots are shown. n = 3. (H) Diagrammatic representation of U-13C glucose (black circles) and U-13C glutamine (gray circles) labeling in human neutrophils. GNG, gluconeogenesis. (I) G6P/F6P isotopologue abundance following culture in U-13C glucose media for 4 h under conditions of normoxia, normoxia with LPS, and hypoxia. n = 4. (J–L) 13C percentage labeling of glycolytic intermediaries (J; n = 4) and isotopologue labeling of TCA cycle and glycolytic intermediaries (K and L; n = 4) following 4 h of culture in U-13C glutamine containing media. (M) Percentage heavy labeling of G6P/F6P following 4 h of culture in the presence of U-13C palmitic acid. n = 4. (N) Schematic diagram and relative abundance of glucose m+3 isotopologue following U-13C pyruvate tracing in neutrophils derived by LC-MS analysis of hydrolyzed glycogen. n = 4. Data represent mean ± SEM. Statistical significance was determined by paired t tests (A, B, and D) or two-way ANOVA with Tukey’s multiple comparisons test (C and J–L) and a one-way ANOVA with Tukey’s multiple comparisons test (N). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005. (J) Significance shown for unstimulated versus LPS stimulated cells across all isotopologues.
Figure 4
Figure 4
Glycogen Storage Capacity Dictates Neutrophil Function and Survival in Gys1loxloxMRP8-cre+/− Mice and Healthy Human Volunteers Exposed to Altitude-Induced Hypoxia (A and B) Neutrophil glycogen content following 6 (A) or 4 h (B) normoxic culture in glucose-deplete media with the glutaminase inhibitor BPTES preventing glutamine breakdown (A; n = 4) and the gluconeogenesis inhibitor MB05032 (B; n = 3). (C–E) Assessment of apoptosis rates using flow cytometry (C) and cellular morphology (D and E) following culture in glutamine-deprived (C) or glucose-deplete media (D and E) under conditions of normoxia and hypoxia ± LPS for 6 (D) and 20 h (C). Data shown as mean ± SEM (C and D) and fold change from DMSO vehicle control. n = 4. (F and G) Neutrophils were challenged with S. aureus (SH1000) at a multiplicity of infection (MOI) of 10 and bacterial killing assessed by flow cytometry. Data shown as fold change from DMSO (F; n = 7) and untreated (G; n = 3) controls. (H) Glycogen content of neutrophils in the bone marrow, blood, and bronchoalveolar lavage (BAL) of untreated and 24 h post-LPS challenge of wild-type mice (WT). n = 3. (I) Glycogen content of circulating and BAL neutrophils of WT and Gys1 knockout mice. n = 3. (J) Assessment of apoptosis rates using flow cytometry following 24 h of culture under standard media conditions. n = 5. (K) In vitro challenge of BAL neutrophils with S. aureus (SH1000) (MOI:10) and bacterial killing assessed by flow cytometry. n = 3. (L–N) Gys1lox/lox MRP8-Cre+/− knockout (GYS1 KO) and Gys1lox/lox MRP8-Cre−/− WT mice were inoculated with 5 × 107 CFU of S. aureus (SH1000) and rectal temperatures (L), total abscess CFU counts (M), and blood neutrophil counts (N) obtained 24 h post-subcutaneous infection. (O–R) Intracellular glycogen levels (O; n = 6), UGP2 (P; n = 8) and GYS1 (Q; n = 7) relative transcript abundance, and apoptosis rates (R; n = 8) were measured in blood neutrophils isolated from healthy human volunteers at baseline (BL) and 3 months post-altitude-induced hypoxia (PA), following culture ex vivo with LPS and hypoxia. Data represent mean ± SEM. Statistical significance was determined by paired t tests (A, B, D–F, K, P, and Q), two-way ANOVA with Sidak’s multiple comparisons test (C, O, and R), one-way ANOVA with Tukey’s multiple comparisons test (C, G, and H), and unpaired t tests (I, J, and L–N). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005, ∗∗∗∗p < 0.001.
Figure 5
Figure 5
COPD Peripheral Blood Neutrophils Are Unable to Regulate Their Glycogen Synthesis, Resulting in Diminished Intracellular Glycogen Stores, Defective Bacterial Killing, and Survival (A–C) Neutrophils from healthy control subjects (HC; open black circle) or patients with COPD (COPD; open blue square) were challenged with either opsonized serotype 14 Streptococcus pneumoniae (S14) (A; n = 7) or Staphylococcus aureus (SH1000) (B; n = 4), at a multiplicity of infection (MOI) of 10 and bacterial killing assessed. Assessment of apoptosis by annexin V/TO-PRO-3 staining of HC and COPD neutrophils following 20 h culture (C; n = 6). (D) Relative of ATP abundance of freshly isolated neutrophils from HC and COPD using RP-HPLC (reversed-phase high-performance liquid chromatography). HC, n = 4; COPD, n = 6. (E and F) Seahorse quantification of ECAR of healthy and COPD peripheral blood neutrophils exposed to SH1000 at an MOI of 10, 25, and 50. n = 4. (G) U-13C glucose incorporation into glucose-6-phosphate/fructose-6-phosphate (G6P/F6P) following 4 h of culture in U-13C glucose containing media under normoxia in the presence (filled symbol) and absence (open symbol) of LPS. n = 5. (H) Glycogen content of HC and COPD neutrophils cultured in glucose-replete and glucose-deplete media for 6 h in the presence and absence of LPS. n = 7. (I and J) Relative transcript abundance of the gluconeogenic gene PEPCK2 (I; n = 7, unstimulated; n = 9, LPS) and glycogen synthesis pathway gene GBE1 (J; n = 7) in HC and COPD neutrophils cultured for 6 h in the presence and absence of LPS normalized to β-actin expression. (K–Q) Healthy control and COPD peripheral blood neutrophils were cultured in U-13C glucose containing media for 4 h under normoxia in the presence and absence of LPS. Total intracellular lactate (K; n = 5), medium lactate (L; n = 5), ribose5P/xylulose5P (M; n = 5), sedoheptulose7P (N; n = 5), NADH (O; n = 4), UDP-glucose (P; n = 5), and UDP-GlcNAc (Q; n = 5) were measured using LC-MS and normalized to protein content. Fold change was determined relative to the paired unstimulated HC control (M). (R) Healthy control and COPD peripheral blood neutrophils were cultured in U-13C glutamine containing media for 4 h under normoxia and total labeled F1,6BP measured using LC-MS. n = 6. Data are expressed as individual data points with mean ± SEM. Statistical significance was determined by paired t tests (A–D and H–R) or two-way ANOVA with Sidak’s multiple comparisons test (E and F). ∗p < 0.05, ∗∗p < 0.01.
Figure 6
Figure 6
A Summary of the Observed Metabolic States of Quiescent, LPS Stimulated, and COPD Neutrophils A diagram showing the metabolic states of resting (A), stimulated (B), and COPD (C) neutrophils showing increased glycolytic activity and glycogen synthesis in response to LPS and defective glycogen cycling and glycolysis in COPD. Genes identified to actively regulate neutrophil glucose transport (Glut1), gluconeogenesis (GNG) (Fbp1 and Pck2), glycogenesis (Gys1, Gbe1, and Ugp2), and glycogenolysis (Pygl) are highlighted in red. Arrow thickness indicates the relative flux through metabolic pathways with glycogenolysis and glucose oxidation highlighted in blue and glycogenesis and gluconeogenesis in green.

References

    1. Bender J.G., Van Epps D.E. Inhibition of human neutrophil function by 6-aminonicotinamide: the role of the hexose monophosphate shunt in cell activation. Immunopharmacology. 1985;10:191–199.
    1. Borregaard N., Herlin T. Energy metabolism of human neutrophils during phagocytosis. J. Clin. Invest. 1982;70:550–557.
    1. Boxer L.A., Baehner R.L., Davis J. The effect of 2-deoxyglucose on guinea pig polymorphonuclear leukocyte phagocytosis. J. Cell. Physiol. 1977;91:89–102.
    1. Cheung Y.Y., Kim S.Y., Yiu W.H., Pan C.-J., Jun H.-S., Ruef R.A., Lee E.J., Westphal H., Mansfield B.C., Chou J.Y. Impaired neutrophil activity and increased susceptibility to bacterial infection in mice lacking glucose-6-phosphatase-β. J. Clin. Invest. 2007;117:784–793.
    1. De Bock K., Georgiadou M., Schoors S., Kuchnio A., Wong B.W., Cantelmo A.R., Quaegebeur A., Ghesquière B., Cauwenberghs S., Eelen G. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell. 2013;154:651–663.
    1. Desai H., Eschberger K., Wrona C., Grove L., Agrawal A., Grant B., Yin J., Parameswaran G.I., Murphy T., Sethi S. Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary disease. Ann. Am. Thorac. Soc. 2014;11:303–309.
    1. Duran J., Saez I., Gruart A., Guinovart J.J., Delgado-García J.M. Impairment in long-term memory formation and learning-dependent synaptic plasticity in mice lacking glycogen synthase in the brain. J. Cereb. Blood Flow Metab. 2013;33:550–556.
    1. Favaro E., Bensaad K., Chong M.G., Tennant D.A., Ferguson D.J.P., Snell C., Steers G., Turley H., Li J.L., Günther U.L. Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab. 2012;16:751–764.
    1. Finisguerra V., Di Conza G., Di Matteo M., Serneels J., Costa S., Thompson A.A.R., Wauters E., Walmsley S., Prenen H., Granot Z. MET is required for the recruitment of anti-tumoural neutrophils. Nature. 2015;522:349–353.
    1. Fossati G., Moulding D.A., Spiller D.G., Moots R.J., White M.R.H., Edwards S.W. The mitochondrial network of human neutrophils: role in chemotaxis, phagocytosis, respiratory burst activation, and commitment to apoptosis. J. Immunol. 2003;170:1964–1972.
    1. Garnett J.P., Nguyen T.T., Moffatt J.D., Pelham E.R., Kalsi K.K., Baker E.H., Baines D.L. Proinflammatory mediators disrupt glucose homeostasis in airway surface liquid. J. Immunol. 2012;189:373–380.
    1. Hogg J.C., Chu F., Utokaparch S., Woods R., Elliott W.M., Buzatu L., Cherniack R.M., Rogers R.M., Sciurba F.C., Coxson H.O., Paré P.D. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004;350:2645–2653.
    1. Jha A.K., Huang S.C.C., Sergushichev A., Lampropoulou V., Ivanova Y., Loginicheva E., Chmielewski K., Stewart K.M., Ashall J., Everts B. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity. 2015;42:419–430.
    1. Jun H.S., Cheung Y.Y., Lee Y.M., Mansfield B.C., Chou J.Y. Glucose-6-phosphatase-β, implicated in a congenital neutropenia syndrome, is essential for macrophage energy homeostasis and functionality. Blood. 2012;119:4047–4055.
    1. Kim S.Y., Jun H.S., Mead P.A., Mansfield B.C., Chou J.Y. Neutrophil stress and apoptosis underlie myeloid dysfunction in glycogen storage disease type Ib. Blood. 2008;111:5704–5711.
    1. Ko C.W., Counihan D., Wu J., Hatzoglou M., Puchowicz M.A., Croniger C.M. Macrophages with a deletion of the phosphoenolpyruvate carboxykinase 1 (Pck1) gene have a more proinflammatory phenotype. J. Biol. Chem. 2018;293:3399–3409.
    1. Ma R., Ji T., Zhang H., Dong W., Chen X., Xu P., Chen D., Liang X., Yin X., Liu Y. A Pck1-directed glycogen metabolic program regulates formation and maintenance of memory CD8+ T cells. Nat. Cell Biol. 2018;20:21–27.
    1. Martin W.H., Hoover D.J., Armento S.J., Stock I.A., McPherson R.K., Danley D.E., Stevenson R.W., Barrett E.J., Treadway J.L. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc. Natl. Acad. Sci. USA. 1998;95:1776–1781.
    1. Mills E.L., Kelly B., Logan A., Costa A.S.H., Varma M., Bryant C.E., Tourlomousis P., Däbritz J.H.M., Gottlieb E., Latorre I. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell. 2016;167:457–470.e13.
    1. Naughton D., Whelan M., Smith E.C., Williams R., Blake D.R., Grootveld M. An investigation of the abnormal metabolic status of synovial fluid from patients with rheumatoid arthritis by high field proton nuclear magnetic resonance spectroscopy. FEBS Lett. 1993;317:135–138.
    1. Neubert D., Lehninger A.L. The effect of oligomycin, gramicidin and other antibiotics on reversal of mitochondrial swelling by adenosine triphosphate. Biochim. Biophys. Acta. 1962;62:556–565.
    1. Obel L.F., Müller M.S., Walls A.B., Sickmann H.M., Bak L.K., Waagepetersen H.S., Schousboe A. Brain glycogen-new perspectives on its metabolic function and regulation at the subcellular level. Front. Neuroenergetics. 2012;4:3.
    1. Pescador N., Villar D., Cifuentes D., Garcia-Rocha M., Ortiz-Barahona A., Vazquez S., Ordoñez A., Cuevas Y., Saez-Morales D., Garcia-Bermejo M.L. Hypoxia promotes glycogen accumulation through hypoxia inducible factor (HIF)-mediated induction of glycogen synthase 1. PLoS ONE. 2010;5:e9644.
    1. Pike L.S., Smift A.L., Croteau N.J., Ferrick D.A., Wu M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim. Biophys. Acta. 2011;1807:726–734.
    1. Raud B., Roy D.G., Divakaruni A.S., Tarasenko T.N., Franke R., Ma E.H., Samborska B., Hsieh W.Y., Wong A.H., Stüve P. Etomoxir actions on regulatory and memory T cells are independent of Cpt1a-mediated fatty acid oxidation. Cell Metab. 2018;28:504–515.e7.
    1. Robinson J.M., Karnovsky M.L., Karnovsky M.J. Glycogen accumulation in polymorphonuclear leukocytes, and other intracellular alterations that occur during inflammation. J. Cell Biol. 1982;95:933–942.
    1. Rousset M., Chevalier G., Rousset J.P., Dussaulx E., Zweibaum A. Presence and cell growth-related variations of glycogen in human colorectal adenocarcinoma cell lines in culture. Cancer Res. 1979;39:531–534.
    1. Sadiku P., Willson J.A., Dickinson R.S., Murphy F., Harris A.J., Lewis A., Sammut D., Mirchandani A.S., Ryan E., Watts E.R. Prolyl hydroxylase 2 inactivation enhances glycogen storage and promotes excessive neutrophilic responses. J. Clin. Invest. 2017;127:3407–3420.
    1. Sbarra A.J., Karnovsky M.L. The biochemical basis of phagocytosis. I. Metabolic changes during the ingestion of particles by polymorphonuclear leukocytes. J. Biol. Chem. 1959;234:1355–1362.
    1. Scott R.B. Glycogen in human peripheral blood leukocytes. I. Characteristics of the synthesis and turnover of glycogen in vitro. J. Clin. Invest. 1968;47:344–352.
    1. Thompson A.A.R., Dickinson R.S., Murphy F., Thomson J.P., Marriott H.M., Tavares A., Willson J., Williams L., Lewis A., Mirchandani A. Hypoxia determines survival outcomes of bacterial infection through HIF-1α dependent re-programming of leukocyte metabolism. Sci. Immunol. 2017;2:eaal2861.
    1. Thwe P.M., Pelgrom L.R., Cooper R., Beauchamp S., Reisz J.A., D’Alessandro A., Everts B., Amiel E. Cell-intrinsic glycogen metabolism supports early glycolytic reprogramming required for dendritic cell immune responses. Cell Metab. 2017;26:558–567.e5.
    1. Tyrakis P.A., Palazon A., Macias D., Lee K.L., Phan A.T., Veliça P., You J., Chia G.S., Sim J., Doedens A. S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate. Nature. 2016;540:236–241.
    1. Valentine W.N., Follette J.H., Lawrence J.S. The glycogen content of human leukocytes in health and in various disease states. J. Clin. Invest. 1953;32:251–257.
    1. Vincent E.E., Sergushichev A., Griss T., Gingras M.C., Samborska B., Ntimbane T., Coelho P.P., Blagih J., Raissi T.C., Choinière L. Mitochondrial phosphoenolpyruvate carboxykinase regulates metabolic adaptation and enables glucose-independent tumor growth. Mol. Cell. 2015;60:195–207.
    1. Walmsley S.R., Print C., Farahi N., Peyssonnaux C., Johnson R.S., Cramer T., Sobolewski A., Condliffe A.M., Cowburn A.S., Johnson N., Chilvers E.R. Hypoxia-induced neutrophil survival is mediated by HIF-1α-dependent NF-kappaB activity. J. Exp. Med. 2005;201:105–115.
    1. Wick A.N., Drury D.R., Nakada H.I., Wolfe J.B. Localization of the primary metabolic block produced by 2-deoxyglucose. J. Biol. Chem. 1957;224:963–969.
    1. Yao C.H., Liu G.Y., Wang R., Moon S.H., Gross R.W., Patti G.J. Identifying off-target effects of etomoxir reveals that carnitine palmitoyltransferase I is essential for cancer cell proliferation independent of β-oxidation. PLoS Biol. 2018;16:e2003782.
    1. Yu S.M., Kim S.J. Endoplasmic reticulum stress (ER-stress) by 2-deoxy-D-glucose (2DG) reduces cyclooxygenase-2 (COX-2) expression and N-glycosylation and induces a loss of COX-2 activity via a Src kinase-dependent pathway in rabbit articular chondrocytes. Exp. Mol. Med. 2010;42:777–786.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe